Literature DB >> 19744130

Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.

Jeffrey R Sawyer1, Erming Tian, Edward Thomas, Mark Koller, Colin Stangeby, Gael Sammartino, Linda Goosen, Charles Swanson, Regina L Binz, Bart Barlogie, John Shaughnessy.   

Abstract

Gene amplification is defined as a copy number (CN) increase in a restricted region of a chromosome arm, and is a mechanism for acquired drug resistance and oncogene activation. In multiple myeloma (MM), high CNs of genes in a 1q12 approximately 23 amplicon have been associated with disease progression and poor prognosis. To investigate the mechanisms for gene amplification in this region in MM, we performed a comprehensive metaphase analysis combining G-banding, fluorescence in situ hybridization, and spectral karyotyping in 67 patients with gain of 1q. In six patients (9%), evidence for at least one breakage-fusion-bridge (BFB) cycle was found. In three patients (4%), extended ladders of 1q12 approximately 23 amplicons were identified. Several key structures that are predicted intermediates in BFB cycles were observed, including: equal-spaced organization of amplicons, inverted repeat organization of amplicons along the same chromosome arm, and deletion of sequences distal to the amplified region. The 1q12 pericentromeric heterochromatin region served as both a recurrent breakpoint as well as a fusion point for sister chromatids, and ultimately bracketed both the proximal and distal boundaries of the amplicon. Our findings provide evidence for a novel BFB mechanism involving 1q12 pericentromeric breakage in the amplification of a large number of genes within a 1q12 approximately 23 amplicon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744130      PMCID: PMC3738438          DOI: 10.1111/j.1365-2141.2009.07869.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  46 in total

1.  New classes of common fragile sites induced by 5-azacytidine and bromodeoxyuridine.

Authors:  G R Sutherland; M I Parslow; E Baker
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

2.  Induction of tumors in mice by genomic hypomethylation.

Authors:  François Gaudet; J Graeme Hodgson; Amir Eden; Laurie Jackson-Grusby; Jessica Dausman; Joe W Gray; Heinrich Leonhardt; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes.

Authors:  T W Glover; C Berger; J Coyle; B Echo
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

4.  Induction of sister chromatid exchanges at common fragile sites.

Authors:  T W Glover; C K Stein
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

5.  Constitutive fragile sites and cancer.

Authors:  J J Yunis; A L Soreng
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

6.  Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells.

Authors:  C Ma; S Martin; B Trask; J L Hamlin
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

7.  Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Authors:  Jun Inoue; Takemi Otsuki; Akira Hirasawa; Issei Imoto; Yoshinobu Matsuo; Shiroh Shimizu; Masafumi Taniwaki; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  5-Azacytidine-induced undercondensations in human chromosomes.

Authors:  M Schmid; T Haaf; D Grunert
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

9.  Region-specific chromatin decondensation and micronucleus formation induced by 5-azacytidine in human TIG-7 cells.

Authors:  T Satoh; K Yamamoto; K F Miura; T Sofuni
Journal:  Cytogenet Genome Res       Date:  2004       Impact factor: 1.636

10.  Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at early steps of mammalian gene amplification.

Authors:  F Toledo; D Le Roscouet; G Buttin; M Debatisse
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

View more
  10 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Cancer-linked satellite 2 DNA hypomethylation does not regulate Sat2 non-coding RNA expression and is initiated by heat shock pathway activation.

Authors:  Gaëlle Tilman; Nausica Arnoult; Sandrine Lenglez; Amandine Van Beneden; Axelle Loriot; Charles De Smet; Anabelle Decottignies
Journal:  Epigenetics       Date:  2012-06-22       Impact factor: 4.528

3.  Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Donald J Johann; Joshua Epstein; Charles M Swanson; Janet L Lukacs; Regina Lichti Binz; Marian Johnson; Gael Sammartino; Maurizio Zangari; Faith E Davies; Frits van Rhee; Gareth J Morgan; Bart Barlogie
Journal:  Blood       Date:  2015-05-05       Impact factor: 22.113

Review 4.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

5.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

6.  Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Joshua Epstein; Donald J Johann; Charles M Swanson; Janet L Lukacs; Marian Johnson; Regina Binz; Angela Boast; Gael Sammartino; Saad Usmani; Maurizio Zangari; Sarah Waheed; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

Review 7.  Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

Authors:  Laurens G L Sand; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  Int J Mol Sci       Date:  2015-07-16       Impact factor: 5.923

Review 8.  Multiple myeloma with high-risk cytogenetics and its treatment approach.

Authors:  Ichiro Hanamura
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.319

Review 9.  Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.

Authors:  Romanos Sklavenitis-Pistofidis; Gad Getz; Irene Ghobrial; Maria Papaioannou
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

10.  Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma.

Authors:  P Tosi; M Imola; A M Mianulli; S Tomassetti; A Merli; A Molinari; S Mangianti; M Ratta; A Isidori; G Visani
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-05       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.